We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Application Forum - Sponsored PaperOpen Accesscc iconby iconnc iconnd icon

A novel ex-vivo application of RNAi for neuroscience

    Louise Baskin

    Thermo Fisher Scientific, Lafayette, CO, USA

    ,
    Stephanie Urschel

    Thermo Fisher Scientific, Lafayette, CO, USA

    &
    Britta Eiberger

    Institute of Anatomy, University of Bon, Germany

    Published Online:https://doi.org/10.2144/000112956

    Introduction

    A large number of patients worldwide suffer from neuronal disorders such as Alzheimer's, Parkinson's, and Huntington's disease. At present, the fundamental molecular mechanisms underlying these and other neuronal diseases remain unclear. Harnessing RNA interference (RNAi) to elucidate the mechanisms leading to such neuronal disorders might help to gain insights finally leading to the development of efficient treatments.

    Using organotypic slice cultures for studies to analyze molecular pathways in neurons is a means of bridging the gap between in vitro cell cultures and in vivo models. In contrast to cultures of primary neurons, ex vivo slice cultures allow the study of primary neurons within the context of an intact cellular network of supporting cells and other neurons, thereby more closely mimicking the in vivo situation. In addition, it is possible to manipulate the cells in slice cultures to optimize parameters and monitor results — all of which is very challenging in rodent in vivo models.

    RNAi in Neuronal Cells

    Up until now the use of small interfering RNA (siRNA) in neuronal cell models was limited by delivery efficiency of siRNA to neuronal cells in vitro and in vivo. Using lipid-based transfection reagents to transfect neuronal cells with siRNA traditionally has been problematic; primarily due to low efficiency of delivery or lipid-induced effects that lead to toxicity. Transfection methods based on electroporation require additional equipment and also may not result in reliably sufficient transfection efficiencies and cell viability.

    In contrast to conventional RNAi delivery methods, Thermo Scientific Dharmacon® Accell™ siRNA allows the delivery of siRNA independent of transfection reagents or instrument-based procedures that may result in loss of cell viability, thus overcoming a major obstacle in working with neuronal cells.

    By applying Accell siRNA in organotypic mouse brain slices, unwanted non-specific delivery effects commonly caused by transfection reagents or instruments are excluded. In addition, long-term effects such as cell differentiation can be easily monitored by repeated addition of Accell siRNA to the cultured slice without detrimental effects to the overall structure or physiology of the tissue.

    Workflow for Delivery of Accell siRNA to Cultured Brain Slices

    Cerebella dissected out of embryonal day 17 and postnatal day 8 C57/Bl6 pups were placed carefully into cold modified Hank's solution (137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 5mM glucose, 2.5 mM CaCl2, 1.2 mM MgSO4, 4.17 mM NaHCO3, pH 7.2) without removing the meninges. After all cerebella were collected, the tissue was embedded in 5 ml (20% wt/vol) liquid gelatin (from porcine skin, type A) dissolved in Hank's solution for 20 min at 37°C in a CO2 incubator. Subsequently, cerebella were mounted onto a sterile specimen disc, and sagittal sections of 250 µm thickness were prepared using a McIlwain tissue chopper. The slices were gently placed in cold Accell delivery media and individual sections were separated under a dissection microscope (Zeiss, Stemi 2000 C). Slices were recovered from the media and transferred in a small volume of liquid onto membranes of tissue culture inserts (Millicell-CM, Millipore, Bedford, MA; 12 mm, pore size 0.4 µm) placed in a 24-well dish with 300 µl Accell delivery mix (Accell delivery media supplemented with 1× B-27 (Gibco) and 1 µM Accell siRNA) using the broad end of a Pasteur pipette. A small amount of media underneath the membrane allowed the sections to attach very well to the membrane. Wells not containing culture inserts were filled with sterile water to increase humidity inside the culture dish. Cultures were kept in a standard cell incubator (37°C, 5% CO2 and 95% humidity) and were harvested after 48, 72 and 96 h of incubation. Cultures were each rinsed twice with ice-cold PBS. Slices were colslected into 40 µl RIPA buffer supplemented with 1× protease inhibitor cocktail (Complete, Roche) and sonicated for 1 min to lyse the tissue. Western blot with 50 µg of tissue lysate per lane was incubated with anti-Cyclophilin B (Abcam, 1: 2,000) and goat-anti-rabbit-HRP (Dako, 1: 30,000) antibodies and detected by (substrate: Super Signal West Femto, Thermo Fisher Scientific).

    Observation of Cellular Penetration by Accell siRNA

    To assess uptake of Accell siRNA, 250 µm cerebellar sections were prepared and cultured as described above. After 3 and 72 h of incubation with Accell Red Non-targeting siRNA, slices were inspected with a Leica DM IRE2 microscope (filter TX2).

    As shown in Figure 1, uptake of Accell siRNA was visible after 3 h of incubation. The most prominent fluorescence was observed in cells of the Purkinje and granule cell layer. After 72 h in culture, fluorescence in the slices was more intense, indicating an increased uptake of Accell siRNA with extended incubation. The addition of B-27 neuronal media supplement enhanced the overall cellular viability and had no observed effect on siRNA uptake (data not shown).

    Figure 1. 

    Figure 1. 3 hours and 72 hours post application of Accell Red Non-targeting control siRNA (Dharmacon cat# D-001960-01). Shutter time 150 ms.

    Demonstration of Knockdown of Cyclophilin B

    To demonstrate target gene knockdown in cultured brain slices using Accell siRNA, the workflow described above was employed to target the housekeeping gene PPIB (Cyclophilin B, NM_011149). Cultured brain slices were assessed following Accell siRNA incubation for three time points (48, 72, 96 h) and the level of remaining protein was evaluated using Western blot analysis. The results of these experiments are presented in Figure 2 and demonstrate the efficacy of Accell technology in providing effective target silencing.

    Figure 2. 

    Figure 2. Accell effectively silenced a target gene in cultured brain slices. Fresh P8 mouse cerebellum slices (250 µm) were incubated in Accell delivery media (Dharmacon cat# B-005000) supplemented with Gibco® B-27 serum-free supplement containing 1 µM Accell siRNA targeting Cyclophilin B (Accell PPIB; Dharmacon cat# D-001920-02) or Accell Non-targeting siRNA #1 (NTC; Dharmacon cat# D-001910-01). Slices were cultured for 48, 72, or 96 h prior to knockdown detection. Tissue was harvested using RIPA-buffer; 50 µg of protein lysate were analysed per sample.

    Summary

    These preliminary studies demonstrated that Accell siRNA can be delivered into cells of a brain slice culture allowing for successful RNAi in neurons. Furthermore, the ease and convenience of this method will enable scientists to use Accell siRNA to empower a variety of applications for the study of neuronal mechanisms and diseases.

    • Medium- to high-throughput RNAi screens to assess gene silencing in neurons.

    • Knockdown of a gene's expression and monitoring the resulting phenotype to evaluate the experimental potential of a knockout mouse of the same gene.

    • The ex vivo model of the cultured brain slice can also serve as a framework to address the discrepancy between anticipated and actual in vivo results, addressing phenotypes such as cellular organization and differentiation.

    Link

    www.thermo.com/dharmacon

    Contact Information

    E-mail:

    Phone: 800-235-9880/303-604-9499